Replimune Stock Jumps 9.73% After First Quarter Selling Its Melanoma Drug Tudriqev
The cancer-drug developer reported a $57.1 million quarterly net loss and said more than 15 institutions are prescribing Tudriqev.
Replimune Group, which develops cancer treatments built on an engineered herpes virus, climbed 9.73% to $14.32 in Wednesday trading, as of 10:56 a.m. ET, adding about $120 million in market value. The move came the day it reported fiscal second-quarter results and said its melanoma drug Tudriqev has reached patients.
A launch with 15 prescribers
More than 15 institutions are now prescribing Tudriqev, the company said. Management told investors on its earnings call that the launch is going very well and that it is eyeing a doubling of treating accounts by year-end.
The company offered formulary and first-script counts rather than patient numbers or revenue guidance. It said it has actively engaged 70% of its initial 200 priority accounts to set up workflows for adopting the drug.
Tudriqev was first delivered to patients on October 6, and the company says it holds more than a year of inventory made in its own facility.
Loss and cash position
The company's quarterly filing shows a net loss of $57.1 million for the period ended September 30. Cash and cash equivalents stood at $307.8 million at the end of September, including about $141.0 million in net proceeds from a stock and pre-funded warrant offering.
A third straight gain
Replimune, a clinical-stage company, had no approved products before Tudriqev. Its second candidate, RP2, is being studied in uveal melanoma, a cancer of the eye, and in liver cancers.
The stock was on pace for its third straight daily gain and its biggest one-day rise since August 12, when it gained 11.6%. Shares were up about 34% for the year as of Tuesday's close, against about 13% for the S&P 500.
Replimune's next scheduled earnings date is Wednesday, November 4.
Correction, Oct. 29, 2026: An earlier version of this story linked a statement from the company's earnings call to a page that did not contain it. The link has been removed.
Sources
- Replimune Group GAAP EPS of -$0.54 beats by $0.21 (REPL:NASDAQ) | Seeking Alpha — seekingalpha.com
- Replimune Reports Fiscal Second Quarter 2027 Financial — globenewswire.com
- The company's filing (Replimune Group) — SEC filing
- Replimune Group — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR